<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01138423</url>
  </required_header>
  <id_info>
    <org_study_id>UMCU-Vasc-14A</org_study_id>
    <nct_id>NCT01138423</nct_id>
  </id_info>
  <brief_title>Treatment of Adiposity Related hypErTension (TARGET)</brief_title>
  <acronym>TARGET</acronym>
  <official_title>A Randomized, Placebo-controlled, Double Blind, 4-period, Cross-over Trial, to Study the Effects of Aliskiren, Hydrochlorothiazide and Moxonidine on Endothelial Dysfunction in Obesity Related Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High blood pressure (hypertension) is an important cause of myocardial infarction and stroke.
      High blood pressure often occurs in people who are overweight. These people frequently also
      have abnormal fat and sugar metabolism. The combination of these problems is called the
      'metabolic syndrome'.

      People with hypertension and obesity currently receive the same drug therapy as people with
      hypertension, but without obesity. Different classes of drugs are thought to be equally
      effective in lowering blood pressure.

      Next to lowering blood pressure, hypertension treatment can have additional effects, like
      changes in blood vessel function (the ability to dilate and constrict) or changes is the
      metabolism of sugar and fat. Particularly in patients with the metabolic syndrome, these
      additional effects are thought to be of great importance, because they can influence the risk
      for cardiovascular diseases.

      The blood pressure lowering mechanism differs between classes of blood pressure lowering
      medication. The purpose of this study is to compare the effects of three types of blood
      pressure lowering medication belonging to different classes. The main outcomes of interest
      will be blood vessel function (the ability to dilate and constrict) and blood pressure.
      Moreover, the effect of treatment on additional outcomes, like metabolism of sugar and fat,
      will be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of obesity related hypertension (ORH) is challenging and has become an important
      global health problem. According to guidelines, most classes of antihypertensives are equally
      effective for the treatment of hypertension. However, these guidelines are based on evidence
      from studies in patients with essential hypertension, but without a specific focus on ORH.
      There is an increasing body of evidence about the complex pathophysiological mechanisms of
      ORH. Adipose tissue dysfunction is commonly regarded as a common soil that eventually causes
      up regulation of the sympathetic nervous system (SNS) and the renin-angiotensin-system (RAS).
      Moreover, development of hypertension is closely related to development of endothelial
      dysfunction, dyslipidemia and disorders of glucose metabolism. The investigators hypothesize
      that treatment with antihypertensives that are directed at down regulation of the SNS
      (moxonidine) and the RAS (aliskiren) will result in more beneficial effects than treatment
      with a diuretic (hydrochlorothiazide), because the latter reduces blood pressure by
      inhibition of sodium resorption, without influencing the underlying disease mechanism. The
      main outcomes of interest are endothelial function and blood pressure, but many secondary
      outcomes are studied too.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial function assessed by Flow Mediated Dilation (FMD)</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean 24-hour systolic/diastolic blood pressure Mean day- and night time systolic/diastolic blood pressure</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Blood pressure (estimated with pulse wave analysis)</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renin-Angiotensin System (RAS) hormone concentrations</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sympathetic nervous system activity, assessed by Muscle Sympathetic Nerve Activity (MSNA) and Heart Rate Variability (HRV)</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of oxidative stress (concentrations of F2-isoprostanes in urine and oxLDL in plasma)</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of inflammation (hs-CRP in plasma)</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional sodium excretion</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness (assessed by pulse wave velocity and the pulse wave analysis augmentation index)</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose tissue function (serum concentrations of adipokines)</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism (serum lipid concentrations)</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity, expressed by homeostatic model assessment (HOMA)</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hypertension</condition>
  <condition>Abdominal Obesity</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrochlorothiazide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Once daily treatment with aliskiren for 8-weeks, according to the following regiment: once daily (morning time) 150 mg during the first 2 weeks, followed by once daily (morning time) 300 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 150 mg on day 1, 2, 3, 4, 5 and 7.</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <other_name>Brand name: Ralisez</other_name>
    <other_name>ATC-code: C09XA02</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxonidine</intervention_name>
    <description>Once daily treatment with moxonidine for 8-weeks, according to the following regiment: once daily (morning time) 0.2 mg during the first 2 weeks, followed by once daily (morning time) 0.4 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 0.2 mg on day 1, 2, 3, 4, 5 and 7.</description>
    <arm_group_label>Moxonidine</arm_group_label>
    <other_name>No brand name (generic product)</other_name>
    <other_name>ATC-code: C02AC05</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Once daily treatment with hydrochlorothiazide for 8-weeks, according to the following regiment: once daily (morning time) 12.5 mg during the first 2 weeks, followed by once daily (morning time) 25 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 12.5 mg on day 1, 2, 3, 4, 5 and 7.</description>
    <arm_group_label>Hydrochlorothiazide</arm_group_label>
    <other_name>No brand name (generic product)</other_name>
    <other_name>ATC-code: C03AA03</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for aliskiren)</intervention_name>
    <description>Once daily treatment with placebo tablets for 8-weeks, according to the following regiment: once daily (morning time) 1 tablet during the first 2 weeks, followed by once daily (morning time) 2 tablets during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.</description>
    <arm_group_label>Moxonidine</arm_group_label>
    <arm_group_label>Hydrochlorothiazide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for moxonidine and hydrochlorothiazide)</intervention_name>
    <description>Once daily treatment with placebo capsules for 8-weeks, according to the following regiment: once daily (morning time) 1 capsule during the first 2 weeks, followed by once daily (morning time) 2 capsules during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patient is a male or post menopausal female, 30-70 years of age on the day of signing
             informed consent. Post menopausal status is assumed if a woman has not experienced a
             menstrual bleed for a minimum of 12 months, assuming that she still has a uterus, and
             is not pregnant or lactating. In women without a uterus, menopause or postmenopause is
             defined by a very high FSH level.

          -  All patients should fulfil the diagnostic criterion of abdominal adiposity: waist
             circumference &gt; 102 cm (men) or &gt; 88 cm (women). The waist circumference is measured
             halfway between the lower rib and iliac crest in standing position.

          -  All patients should fulfil the diagnostic criterium for hypertension: systolic blood
             pressure &gt;/= 130 mmHg and/or diastolic blood pressure &gt;/= 85 mmHg during both visits.
             Blood pressure is assessed by office readings in accordance with current guidelines
             for hypertension diagnosis. The patient needs to be seated some minutes before and
             during the measurement. The cuff size should be adjusted to the patients' arm
             circumference and needs to be on the same height level as the patients' sternum during
             the measurements. Blood pressure is determined to a 2 mmHg accuracy-level. Blood
             pressure is measured on both arms during the first visit. In both measurements differ
             more than 10 mmHg, the highest value is taken. After at least 15 seconds, the
             measurement is repeated during the same visit. The highest mean of the two
             measurements on the same arm is considered as the actual blood pressure value.

          -  Patients should fulfil one or more of the following criteria to meet the definition of
             the metabolic syndrome: 1)Hypertriglyceridemia (serum triglycerides &gt; 1.7 mmol/L); 2)
             Low High-density lipoprotein (HDL)-cholesterol (serum HDL-cholesterol &lt; 1.04 mmol/L
             (men) or &lt; 1.29 mmol/L (women)); 3)High fasting glucose (fasting serum glucose &gt; 5.6
             mmol/L).

          -  Patient understands the study procedures, alternative treatments available, and risks
             involved with the study and voluntarily agrees to participate by giving written
             informed consent.

        Exclusion criteria:

          -  Systolic blood pressure &gt; 180 mmHg and/or diastolic blood pressure &gt; 110 mmHg during
             one or more screening measurements.

          -  Body Mass Index (BMI) &gt; 35 kg/m2

          -  Current smoking or smoking during the previous 3 months

          -  Use of &quot;recreational&quot; or illicit drugs

          -  Recent history (within the last year) of alcohol abuse or dependence.

          -  History of hypersensitivity reactions or intolerance to any (components of) medication
             used in this trial.

          -  Current / recent participation (within 30 days of signing informed consent) in a study
             with an investigational compound or device.

          -  Laboratory values as follows: Hemoglobin (Hb) &lt; 8,6 mmol/L (men) or &lt; 7.4 mmol/L
             (women); TSH &lt;0.3 mcIU/mL or &gt; 5.0 mcIU/mL; Potassium &lt; 3,8 mmol/L or &gt; 5,0 mmol/L;
             Sodium &lt; 136 mmol/L or &gt; 146 mmol/L; MDRD &lt; 60 mL/min/1,73m2

          -  Medical conditions as follows: Resistant hypertension (blood pressure above target
             level, despite 3 antihypertensives, including a diuretic); Secondary hypertension;
             Congestive Heart Failure; Atherosclerotic vascular disease (As per NCEP ATP III and
             AHA/ACC Guidelines); Cardiac arrhythmia's, for example bradycardia, atrial
             fibrillation, sick-sinus syndrome, sinoatrial block, atrioventricular block or any
             other arrhythmia; Obstructive sleep apnea syndrome (OSAS) or a score of 10 or higher
             on the Epworth Sleepiness Scale questionnaire; Serious liver function disorders
             (Child-Pugh-Class C); COPD (GOLD classification of severity 2 or higher); Celiac
             disease or other significant intestinal malabsorption; Malignancy â‰¤ 5 years prior to
             signing informed consent, except for adequately treated basal or squamous cell skin
             cancer or in situ cervical cancer; Mental instability or major psychiatric illness;
             Polyneuropathy or clinical suspicion for autonomic nervous system dysfunction; Any
             diseases that would limit or complicate study evaluation or participation; Any
             diseases or screening abnormalities that call for treatment that can not be postponed
             until after the study period without causing harm.

          -  Any concomitant medication, particularly antihypertensive co-medication, glucose
             lowering medication, lipid lowering drugs, systemic corticosteroids, birth control
             pills and vitamin C or E supplements, but also any other kinds of drugs, including
             over the counter medication. Exceptions can be made for the following categories of
             drugs: paracetamol; proton-pump inhibitors; topical creams and unguents that do not
             lead to uptake of any of the active components into the circulation (in case of
             steroid creams: class II or lower); inhalation medication, nasal sprays and eye drops
             that do not lead to uptake of any of the active components into the circulation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>F.L.J. Visseren, Professor (MD PhD)</last_name>
    <role>Study Chair</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>W. Spiering, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2010</study_first_submitted>
  <study_first_submitted_qc>June 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2010</study_first_posted>
  <last_update_submitted>February 23, 2012</last_update_submitted>
  <last_update_submitted_qc>February 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2012</last_update_posted>
  <responsible_party>
    <name_title>dr. W. Spiering</name_title>
    <organization>University Medical Center Utrecht</organization>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Metabolic Syndrome X</keyword>
  <keyword>Obesity</keyword>
  <keyword>Adiposity</keyword>
  <keyword>Clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Obesity, Abdominal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxonidine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

